This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Osborne, C. S.
Right arrow Articles by Ryder, N. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osborne, C. S.
Right arrow Articles by Ryder, N. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2006, p. 2234-2236, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.01600-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Biological, Biochemical, and Molecular Characterization of a New Clinical Trichophyton rubrum Isolate Resistant to Terbinafine

Colin S. Osborne,* Ingrid Leitner, Bettina Hofbauer, Ceri A. Fielding,{dagger} Bertrand Favre,{ddagger} and Neil S. Ryder§

Infectious Diseases, Novartis Institutes for BioMedical Research, 1235 Vienna, Austria

Received 16 December 2005/ Returned for modification 24 January 2006/ Accepted 26 March 2006

We have characterized a new clinical strain of Trichophyton rubrum highly resistant to terbinafine but exhibiting normal susceptibility to drugs with other mechanisms of action. Resistance to terbinafine in this strain is caused by a missense mutation in the squalene epoxidase gene leading to the amino acid substitution F397L.


* Corresponding author. Mailing address: Infectious Diseases, Room 8654, Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, MA 02139. Phone: (617) 871 3142. Fax: (617) 871 7047. E-mail: colin.osborne{at}novartis.com.

{dagger} Present address: Infection and Immunity, University of Wales College of Medicine, Henry Wellcome Research Institute, Heath Park, Cardiff CF14 4XX, United Kingdom.

{ddagger} Present address: Department of Dermatology, Hospital of Beaumont CHUV, 1011 Lausanne, Switzerland.

§ Present address: Infectious Diseases, Novartis Institutes for Biomedical Research, Inc., Cambridge, MA 02139.


Antimicrobial Agents and Chemotherapy, June 2006, p. 2234-2236, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.01600-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Ruckenstuhl, C., Lang, S., Poschenel, A., Eidenberger, A., Baral, P. K., Kohut, P., Hapala, I., Gruber, K., Turnowsky, F. (2007). Characterization of Squalene Epoxidase of Saccharomyces cerevisiae by Applying Terbinafine-Sensitive Variants. Antimicrob. Agents Chemother. 51: 275-284 [Abstract] [Full Text]